期刊文献+

TUR-Bt术后不同溶剂配制吡柔比星行膀胱灌注不良反应情况的对照研究 被引量:1

Comparative study of adverse reactions in using different solvents in preparation of pirarubicin for bladder irrigation after TUR-Bt
下载PDF
导出
摘要 目的探讨0.9%氯化钠溶液(NS)和5%葡萄糖溶液(GS)配制吡柔比星(THP)在经尿道膀胱肿瘤电切术(TUR-Bt)后膀胱灌注的不良反应。方法选取2011年6月—2013年6月双流县第一人民医院收治的浅表性膀胱尿路上皮癌患者60例,随机分为NS组和GS组,各30例。NS组给予THP 40mg+NS 40ml;GS组给予THP 40mg+GS 40ml。观察两组不良反应并随访。结果 GS组不良反应发生率低于NS组,差异有统计学意义(P<0.05)。结论 GS配制THP在TUR-Bt后膀胱灌注对于预防浅表性膀胱尿路上皮癌术后复发有良好的临床疗效,且不良反应更少。 Objective To investigate the adverse reaction of using physiological saline( 0. 9% NS) and 5% glucose( GS) in preparation of pirarubicin( THP) for bladder irrigation after transurethral resection of bladder tumor( TUR- Bt).Methods A total of 60 bladder urothelial carcinoma paitents after TUR- Bt in the First People’s Hospital of Shuangliu County from June 2011 to June 2013 were selected, they were randomly divided into NS group and GS group,30 cases in each group. NS group were given THP 40 mg + NS 40 ml,GS group were given THP 40 mg + GS 40 ml. Adverse reaction of two groups were observed and patients were followed- up. Results Adverse reaction rate of GS group was lower than NS group( P <0. 05). Conclusion The efficacy of both using 0. 9% NS and 5% glucose in preparation pirarubicin for bladder irrigation after TUR- Bt is good,however 0. 9% NS may cause significant bladder irritation and bladder superficial ulcer.
出处 《临床合理用药杂志》 2016年第3期169-170,共2页 Chinese Journal of Clinical Rational Drug Use
关键词 膀胱肿瘤 经尿道膀胱肿瘤电切术 吡柔比星 化学疗法 肿瘤 局部灌注 药物毒性 Urinary bladder neoplasms Transurethral resection of bladder tumor Pirarubicin Chemotherapy cancer regional perfusion Drug toxicity
  • 相关文献

参考文献7

二级参考文献50

  • 1兰卫华,靳风烁,王洛夫,张军,孙中义,谢芳.卡介苗与丝裂霉素C膀胱灌注预防国人膀胱癌复发的比较的Meta分析[J].临床泌尿外科杂志,2006,21(2):145-148. 被引量:10
  • 2张广健,吴长利,韩瑞发,赵玉干,马腾骧,王广有,王凡.膀胱肿瘤抗药机制的实验研究[J].中华泌尿外科杂志,1996,17(4):203-206. 被引量:26
  • 3顾方六 吴阶平.尿路上皮肿瘤临床.泌尿外科[M].济南:山东科学技术出版社,1993.464.
  • 4吴阶平,泌尿外科,1993年,444页
  • 5Yoo S, You D, Jeong I G, et al. Does radical cystectomy improve o- verall survival in octogenarians with muscle-invasive bladder cancer? [J]. KoreanJUrol, 2011, 52(7): 446 -451.
  • 6Millan-Rodriguez F, Chechile-Toniolo C, Salvador-Bayan'i J, et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer[J]. J Urol, 2000, 163(1) : 73 -78.
  • 7Mostofi F K, Sorbin L H, Torloni H. Histologic typing of urinary blad- der tumours. International classification of tumours, No 10 [ R ]. Gene-va: WHO, 1973.
  • 8Sobin L H, Gospodariwicz M K, Wittekind C. TNM Classification of Malignant Tumours. UICC International Union Against Cancer [ M ]. 7th ed. Oxford : Wiley-Blackwell, 2009 : 262 - 265.
  • 9Sauter G, Algaba F, Amin M, et al. Tumour of urinary system: non- invasive urothelial neoplasia[ R]//Eble J N, Sauter G, Epstein J I, et al. WI-IO Classification of Tumour of urinary system and male genital organs. Lyon: IARCC Press, 2004.
  • 10Sylvester R J, van-der-Meijden A P, Oosterlinck W, et al. Predicting re- currence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables : a combined analysis of 2596 patients from seven EORTC trials[J]. Eur Urol, 2006, 49(3) : 466 -477.

共引文献250

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部